The Zacks Analyst Blog Highlights: Isis Pharmaceuticals, Inc., Sanofi, GlaxoSmithKline, OncoGenex and Teva Pharmaceuticals

    The Zacks Analyst Blog Highlights: Isis Pharmaceuticals, Inc., Sanofi,
             GlaxoSmithKline, OncoGenex and Teva Pharmaceuticals

PR Newswire

CHICAGO, Jan. 14, 2013

CHICAGO, Jan. 14, 2013 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Isis Pharmaceuticals (ISIS),
Sanofi (SNY), GlaxoSmithKline(GSK), OncoGenex (OGXI) and Teva


Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks
are offered free.

Here are highlights from Monday's Analyst Blog:

Isis Pharma Updates on Pipeline

Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline.
Isis Pharma boasts of a robust pipeline. The company believes 5 of its
pipeline candidates can get approval within the next five years. Isis Pharma
expects data (phase II or phase III) on nine of its pipeline candidates in

Isis Pharma's lead pipeline candidate, Kynamro (mipomersen), is a second
generation compound being developed in collaboration with Sanofi (SNY) for the
treatment of familial hypercholesterolemia (FH). Isis Pharma received a major
boost in October 2012 when the Food and Drug Administration's (FDA)
Endocrinologic and Metabolic Drugs Advisory Committee voted (9 - 6) in favor
of approving the company's lead pipeline candidate, Kynamro. A response from
the FDA should be out by Jan 29, 2013.

However, we note that in Dec 2012, the Committee for Medicinal Products for
Human Use (CHMP) of the European Medicines Agency (EMA) rendered a negative
opinion on the approval of Kynamro.

Another interesting candidate at Isis Pharma is ISIS-TTRRx. The candidate is
being co-developed with GlaxoSmithKline (GSK) for the treatment of
transthyretin (TTR) amyloidosis. The companies plan to initiate a
registration-directed phase II/III study evaluating the efficacy of ISIS-TTRRx
on neurological dysfunction and quality-of-life in patients with familial
amyloid polyneuropathy (FAP), a type of TTR amyloidosis, shortly. The
candidate received fast track designation from the FDA.

Other promising candidates in Isis Pharma's pipeline include oncology drug,
OGX-011 and EXC 001 for unwanted scarring. For OGX-011, the company has
partnered with OncoGenex (OGXI) and Teva Pharmaceuticals (TEVA). Data from a
phase III trial evaluating OGX-011 in prostate cancer is expected to be
released at the end of 2013.

Isis Pharma carries a Zacks Rank #3 (Hold) in the short run. Though impressed
by Isis Pharma's pipeline, we expect investor focus to remain on the FDA's
decision on Kynamro.

Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks
are offered free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the

Follow us on Twitter:

Join us on Facebook:

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.